Need Assistance?
  • US & Canada:
    +
  • UK: +

TRH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

It is a TRH analog that has improved in vitro and in vivo biostability.

Category
Others
Catalog number
BAT-015389
CAS number
34367-54-9
Molecular Formula
C17H24N6O4
Molecular Weight
376.41
TRH
IUPAC Name
(2S)-N-[(2S)-1-[(2S)-2-amino-3-(3-methylimidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]-5-oxopyrrolidine-2-carboxamide
Synonyms
(His(π-Me)2)-TRH; (His(3-Me)2)-TRH; Pyroglutamyl-3-methylhistidyl-prolinamide; 3-Mehis-trh; 3-Methylhistidine-trh; 3-Me-Trh; 3-Me-His(2)trh; Pglu-3-Me-his-pro-NH2; 3-Methyl-thyrotropin-releasing hormone; 3-Methyl-L-histidyl-N-{[(2S)-5-oxo-2-pyrrolidinyl]carbonyl}-L-prolinamide
Appearance
White Crystalline Solid
Purity
95%
Density
1.6±0.1 g/cm3
Boiling Point
800.2±65.0°C at 760 mmHg
Sequence
Pyr-His(3-Me)-Pro-NH2
Storage
Store at -20°C
Solubility
Soluble in Water
InChI
InChI=1S/C17H24N6O4/c1-22-9-19-8-10(22)7-11(18)17(27)23-6-2-3-13(23)16(26)21-15(25)12-4-5-14(24)20-12/h8-9,11-13H,2-7,18H2,1H3,(H,20,24)(H,21,25,26)/t11-,12-,13-/m0/s1
InChI Key
QQOVFOJJOXRGOK-AVGNSLFASA-N
Canonical SMILES
CN1C=NC=C1CC(C(=O)N2CCCC2C(=O)NC(=O)C3CCC(=O)N3)N
1. The Mini-TRH Test
Johan Spoov Pharmacopsychiatry. 2022 Dec 9. doi: 10.1055/a-1978-8348. Online ahead of print.
Thyrotropin-releasing hormone (TRH), at doses lower than those needed to stimulate prolactin secretion directly, can almost completely antagonize dopamine inhibition of prolactin release. In normal men, prolactin increases 15 min following an i. v. bolus of 12.5 µg TRH (the mini-TRH test), but not the maximal prolactin response to TRH or basal prolactin, positively correlated with prolactin response to haloperidol and negatively with 24-h urinary excretion of homovanillic acid (HVA). These results suggest that the mini-TRH test is a better estimate of dopamine inhibition of prolactin release than the maximal prolactin response or basal prolactin level. A recent neuroimaging study suggested that in schizophrenia, there is a widely distributed defect in extrastriatal dopamine release, but the patients were not in the most acute phase of psychosis. The evidence is reviewed that this defect extends to tuberoinfundibular dopamine (TIDA) and which symptoms are associated with the test. In patients with acute nonaffective psychosis, the mini-TRH test positively correlated with nonparanoid delusions and memory dysfunction, indicating decreased dopamine transmission in association with these symptoms. In patients with acute drug-naïve first-episode schizophrenia, the mini-TRH test negatively correlated with negative disorganization symptoms and with basal prolactin. The latter correlation suggests the contribution of factors related to maximal prolactin stimulation by TRH; therefore, an alternative dose of 6.25 μg TRH could be used for the mini-TRH test in first-episode patients, allowed by increased sensitivity of the present prolactin tests. Future studies are needed to investigate whether the mini-TRH test could help in finding the optimal antipsychotic medication.
2. Biochemical and physiological insights into TRH receptor-mediated signaling
Radka Trubacova, Zdenka Drastichova, Jiri Novotny Front Cell Dev Biol. 2022 Sep 6;10:981452. doi: 10.3389/fcell.2022.981452. eCollection 2022.
Thyrotropin-releasing hormone (TRH) is an important endocrine agent that regulates the function of cells in the anterior pituitary and the central and peripheral nervous systems. By controlling the synthesis and release of thyroid hormones, TRH affects many physiological functions, including energy homeostasis. This hormone exerts its effects through G protein-coupled TRH receptors, which signal primarily through Gq/11 but may also utilize other G protein classes under certain conditions. Because of the potential therapeutic benefit, considerable attention has been devoted to the synthesis of new TRH analogs that may have some advantageous properties compared with TRH. In this context, it may be interesting to consider the phenomenon of biased agonism and signaling at the TRH receptor. This possibility is supported by some recent findings. Although knowledge about the mechanisms of TRH receptor-mediated signaling has increased steadily over the past decades, there are still many unanswered questions, particularly about the molecular details of post-receptor signaling. In this review, we summarize what has been learned to date about TRH receptor-mediated signaling, including some previously undiscussed information, and point to future directions in TRH research that may offer new insights into the molecular mechanisms of TRH receptor-triggered actions and possible ways to modulate TRH receptor-mediated signaling.
3. TRH-like peptides
R Bílek, M Bičíková, L Šafařík Physiol Res. 2011;60(2):207-15. doi: 10.33549/physiolres.932075. Epub 2010 Nov 29.
TRH-like peptides are characterized by substitution of basic amino acid histidine (related to authentic TRH) with neutral or acidic amino acid, like glutamic acid, phenylalanine, glutamine, tyrosine, leucin, valin, aspartic acid and asparagine. The presence of extrahypothalamic TRH-like peptides was reported in peripheral tissues including gastrointestinal tract, placenta, neural tissues, male reproductive system and certain endocrine tissues. Work deals with the biological function of TRH-like peptides in different parts of organisms where various mechanisms may serve for realisation of biological function of TRH-like peptides as negative feedback to the pituitary exerted by the TRH-like peptides, the role of pEEPam such as fertilization-promoting peptide, the mechanism influencing the proliferative ability of prostatic tissues, the neuroprotective and antidepressant function of TRH-like peptides in brain and the regulation of thyroid status by TRH-like peptides.
Online Inquiry
Verification code
Inquiry Basket